Labcorp announces 2023 first quarter results

Company updates full-year guidance first quarter base business revenue grew 10%, while total revenue and earnings were down due to covid-19 testing revenue: q1 of $3.8 billion versus $3.9 billion last year diluted eps: q1 of $2.39 versus $5.23 last year adjusted eps: q1 of $3.82 versus $6.11 last year free cash flow: q1 of $27 million versus $239 million last year planned spin of clinical development business remains on schedule for mid-2023 full-year 2023 guidance: adjusted eps narrowed to $16.25 to $17.75 with midpoint unchanged and free cash flow remains at $1.0 billion to $1.2 billion burlington, n.c. , april 25, 2023 /prnewswire/ -- labcorp (nyse: lh), a leading global life sciences company, today announced results for the first quarter ended march 31, 2023, and updated full-year guidance.
LH Ratings Summary
LH Quant Ranking